Movers and Shakers : Pharma Matters Report
SECTION I: INTRODUCTION
During the second quarter, we saw significant progress with defining the generic drug user fee program. On seven separate occasions, the FDA met with the representatives of the generic industry, including both finished dose and active ingredient manufacturers, to discuss the generic drug review program.
☞ 자세한 내용은 첨부파일을 참고하시기 바랍니다.